SEC Info - Mimedx Group, Inc. - ‘8-K’ for 5/3/21

SEC Info℠

Home

Help

Please Sign In

Mimedx Group, Inc. – ‘8-K’ for 5/3/21

On: Monday, 5/3/21, at 8:00am ET · For: 5/3/21 · Accession #: 1376339-21-39 · File #: 1-35887

  As Of               Filer                 Filing    For·On·As Docs:Size

 5/03/21  Mimedx Group, Inc.                8-K:7,9     5/03/21   14:672K

Current Report — Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     28K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     62K 
 3: EX-99.2     Miscellaneous Exhibit                               HTML     20K 
10: R1          Cover Page Document                                 HTML     46K 
12: XML         IDEA XML File -- Filing Summary                      XML     13K 
 9: XML         XBRL Instance -- mdxg-20210503_htm                   XML     22K 
11: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 5: EX-101.CAL  XBRL Calculations -- mdxg-20210503_cal               XML      7K 
 6: EX-101.DEF  XBRL Definitions -- mdxg-20210503_def                XML      9K 
 7: EX-101.LAB  XBRL Labels -- mdxg-20210503_lab                     XML     71K 
 8: EX-101.PRE  XBRL Presentations -- mdxg-20210503_pre              XML     35K 
 4: EX-101.SCH  XBRL Schema -- mdxg-20210503                         XSD     12K 
13: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    18K 
14: ZIP         XBRL Zipped Folder -- 0001376339-21-000039-xbrl      Zip     35K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C:

mdxg-20210503

i 0001376339 i false00013763392021-05-032021-05-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

____________________

FORM i 8-K

____________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): i May 3, 2021

i MIMEDX GROUP, INC.

(Exact name of registrant as specified in charter)

i Florida

i 001-35887

i 26-2792552

(State or other jurisdiction

(Commission

(IRS Employer

of incorporation)

File Number)

Identification No.)

i 1775 West Oak Commons Ct., NE, i Marietta i GA i 30062

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: ( i 770) i 651-9100

____________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


i ☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i ☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i ☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i ☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange
on which registered

i Common Stock, $0.001 par value per share

i MDXG

i The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD.

On May 3, 2021, MiMedx Group, Inc. (the "Company" or the "Registrant") issued a press release announcing that it had filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with its 2021 Annual Meeting of Shareholders to be held virtually on May 27, 2021 at 10:00 a.m. Eastern Time at www.cesonlineservices.com/mdxg21_vm. The press release also announced that in conjunction with the definitive proxy filing, MiMedx has mailed a letter to shareholders detailing the decisive actions the Board and management team have taken to create shareholder value by transforming MiMedx into a stronger company that is well-positioned to capitalize on the growth opportunities in the regenerative medicine industry. MiMedx’s definitive proxy materials, letter to shareholders and other relevant information can be found at https://votemimedx.com/. The foregoing summary of the press release is qualified in its entirely by reference to the full text of the press release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Also on May 3, 2021, the Company published a letter to healthcare professionals regarding the expected effect of the end of the U.S. Food and Drug Administration's enforcement discretion. The letter explains that the FDA's actions apply to all companies and indicates which of the Company's products it expects to be affected. The foregoing summary of the letter is qualified in its entirely by reference to the full text of the letter which is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.

In addition, MiMedx disclaims any inference regarding the materiality of such information which otherwise may arise as a result of its furnishing such information under Item 7.01 of this Current Report on Form 8-K. Information contained on the website https://votemimedx.com/ is not incorporated by reference into this Current Report on Form 8-K. The information in the preceding paragraph, as well as Exhibit 99.1 and Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section. It may only be incorporated by reference into another filing under the Exchange Act or Securities Act of 1933 if such subsequent filing specifically references Section 7.01 of this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.


Exhibit No.						Description of Exhibit

99.1						Press Release dated May 3, 2021.
99.2						Letter to Healthcare Professionals dated May 3, 2021.
104						The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Exchange Act, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


		MIMEDX GROUP, INC.

Date: May 3, 2021	By:	/s/ *Peter M. Carlson*
		Peter M. Carlson Chief Financial Officer

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

	5/27/21	4, 8-K
Filed on / For Period end:	5/3/21	4, DEFA14A, DEFC14A
		List all Filings

↑Top

Filing Submission 0001376339-21-000039 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Mimedx Group, Inc. – ‘8-K’ for 5/3/21

On: Monday, 5/3/21, at 8:00am ET · For: 5/3/21 · Accession #: 1376339-21-39 · File #: 1-35887

Previous ‘8-K’: ‘8-K’ on / for 4/28/21 · Next: ‘8-K’ on / for 5/12/21 · Latest: ‘8-K’ on / for 3/27/24

Current Report — Form 8-KFiling Table of Contents

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference

Current Report — Form 8-K
Filing Table of Contents